Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 10 unusual trades. Delving into the ...
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell ...
That latest invention — an electromagnetic system capable of separating oil from water — scored her another award at the Regeneron ISEF this year. “Crude oil spills destroy shorelines, imbalance ...
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at $1,152.00. Discover top-rated stocks from highly ranked ...
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has announced positive Phase II results for two novel monoclonal antibodies targeting distinct domains of Factor XI, supporting its bid to bring new ...
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results … ...
Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year. The company said REGN7508 is ...
Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...
A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer ...
Regeneron (REGN) Pharmaceuticals announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 is designed to maximize anticoagulant ...
TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback